Rare disease pharmacy PANTHERx Rare announced on Friday that it is chosen by California-based Soleno Therapeutics as the specialty pharmacy for the distribution of VYKAT XR (diazoxide choline extended-release tablets).

VYKAT XR is a once daily oral tablet indicated for the treatment of hyperphagia in individuals four years of age and older with Prader-Willi syndrome (PWS). It is the first and only FDA-approved treatment for hyperphagia in individuals with PWS.

Bansi Nagji, PANTHERx CEO, said, 'We are pleased to be selected by Soleno Therapeutics for the distribution of VYKAT XR, the first and only FDA-approved treatment for hyperphagia in individuals with PWS. We believe this medicine has the potential to make a meaningful difference in the lives of the individuals suffering from this rare disease and we look forward to supporting individuals living with PWS and their families in accessing this important therapy.'